Publication Details
Abstract
Zilebesiran, a novel GalNAc-conjugated small interfering RNA (siRNA) therapeutic has potential in the treatment of hypertension. Zilebesiran has a distinctive alternative MOA as a liver-targeted therapy that is distinct than traditional antihypertensive medications achieved through inhibiting the angiotensinogen (AGT) gene. By facilitating chronic effects, this intervention not only lowers blood pressure but also treats the essential pathophysiological process of hypertension. Herein we review the pharmacodynamics, hepatic targeting, and other properties of Zilebesiran that may make it a transformative therapeutic for hypertension. Here, we assess its delivery through GalNAc conjugation, siRNA mechanism of action, as well as pharmacologic effects on blood pressure and organ protection. By reviewing clinical trials and current research, this article discusses the safety, efficacy, and outlook of Zilebesiran for cardiovascular therapeutics (Alnylam Pharmaceuticals, 2025; KARDIA-1 Study Group, 2025).